BioSpace News Archive

Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of idiopathic pulmonary fibrosis (IPF).

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the start of a preclinical collaboration on Kabuki Syndrome with researchers from Kennedy Krieger Institute and Johns Hopkins University.

IVERIC Bio, Inc. reported that on May 2, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to six newly-hired, non-executive employees.

Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.

Avilar Therapeutics today announced that members of the company’s leadership team will be featured speakers on advances in the protein degradation field at two upcoming drug discovery conferences.

TecTraum Inc., dedicated to providing the world’s first point-of-care treatment for concussions, announced complete enrollment status for a clinical trial that began in fall of 2019 using its flagship technology, pro2cool®.

Graphite Bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to GPH101 for the treatment of sickle cell disease (SCD).

Lassen Therapeutics today announced upcoming presentations of new data on its novel IL-11 receptor-blocking antibody at the American Thoracic Society (ATS) Annual Meeting being held in San Francisco, May 13-18, 2022.

Modular Medical, Inc., announced that it has entered into a securities purchase agreement with institutional investor Sio Capital Management in connection with a registered direct offering of an aggregate of 449,438 shares of its common stock at an offering price of $4.45 per share.

Revance Therapeutics, Inc. today announced that the company will release first quarter financial results on Tuesday, May 10, 2022 after the close of market.